NEW YORK, Nov. 09, 2016 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InfuSystem Holdings, Inc. (“InfuSystem” or the “Company”) (NYSE MKT:INFU) of the January 9, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased InfuSystem stock or options between May 12, 2015 and November 7, 2016 (the “Class Period”). The case, Lechner v. InfuSystem Holdings, Inc. et al, No.16-cv-08295 was filed on November 8, 2016.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to maintain effective internal control over financial reporting and by releasing misguided financial statements.
Specifically, on November 7, 2016, the Company filed a Form 8-K with the Securities Exchange Commission stating that Company’s audited financial statements for the fiscal year ended December 31, 2015, and the Company’s unaudited financial statements for each of the fiscal quarters ended March 31, 2015 through June 30, 2016, should no longer be relied upon. The Company claimed that these statements contained an overstatement of estimated accounts receivable collections which in turn overstated revenues.
After the announcement, InfuSystem’s share price fell from $ 2.60 per share on November 4, 2016 to a closing price of $1.60 on November 7, 2016—a $1 or a 38.5% drop.
Request more information now by clicking here: www.faruqilaw.com/INFU. There is no cost or obligation to you.
Take Action
If you invested in InfuSystem stock or options between May 12, 2015 and November 7, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/INFU. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding InfuSystem’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. [email protected] Telephone: (877) 247-4292 or (212) 983-9330


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



